N -Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy
ACS Chemical Biology · 2023
DOI: 10.1021/acschembio.3c00085 ↗At a glance
Journal article in ACS Chemical Biology, 2023. Written by Matthew E Griffin and 2 co-authors. Institution: Department of Immunology and Microbiology, Scripps Research, La Jolla, California 92037, United States. Major MEDLINE topics: Immune Checkpoint Inhibitors, Adjuvants, Immunologic. Cited 14 times so far (Crossref); 40 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, National Cancer Institute, Melanoma Research Foundation.
Abstract (original language)
The characterization of microbiota mechanisms in health and disease has reinvigorated pattern recognition receptors as prominent targets for immunotherapy. Notably, our recent studies on Enterococcus species revealed peptidoglycan remodeling and activation of NOD2 as key mechanisms for microbiota enhancement of immune checkpoint inhibitor therapy. Inspired by this work and other studies of NOD2 activation, we performed in silico ligand screening and developed N-arylpyrazole dipeptides as novel NOD2 agonists. Importantly, our N-arylpyrazole NOD2 agonist is enantiomer-specific and effective at promoting immune checkpoint inhibitor therapy and requires NOD2 for activity in vivo. Given the significant functions of NOD2 in innate and adaptive immunity, these next-generation agonists afford new therapeutic leads and adjuvants for a variety of NOD2-responsive diseases.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Immunology and Microbiology, Scripps Research, La Jolla, California 92037, United States.
- Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States.
- Laboratory of Chemical Biology and Microbial Pathogenesis, The Rockefeller University, New York, New York 10065, United States.
- Department of Chemistry, Scripps Research, La Jolla, California 92037, United States.
ORCID profiles: Matthew E Griffin, Taku Tsukidate, Howard C Hang
Funding
- NCI NIH HHS
- National Cancer Institute
- Melanoma Research Foundation
- Rockefeller University
- Hope Funds for Cancer Research
- Takenaka Scholarship Foundation
Cite
APA
Griffin, M. E., Tsukidate, T., & Hang, H. C. (2023). N -Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy. ACS Chemical Biology. https://doi.org/10.1021/acschembio.3c00085
Vancouver
Griffin ME, Tsukidate T, Hang HC. N -Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy. ACS Chemical Biology. 2023. doi:10.1021/acschembio.3c00085
BibTeX
@article{Griffin2023,
author = {Griffin, Matthew E and Tsukidate, Taku and Hang, Howard C},
title = {N -Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy},
journal = {ACS Chemical Biology},
year = {2023},
doi = {10.1021/acschembio.3c00085}
}
EUVIMED